[
    {
        "other_ids": [],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "SEQUENTIAL_ASSIGNMENT",
        "lead_org": "BeiGene",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Phase 1a (dose escalation): Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available, not tolerated or refused, and who have not received prior therapy targeting HPK1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Phase 1b (dose expansion): Participant with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors, including non-small cell lung cancer, esophageal cancer or gastric/Gastroesophageal junction cancer (other solid tumors may be included) who have progressed following systemic anticancer therapies or have no prior systemic treatment for advanced disease"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "At least 1 measurable lesion as defined per RECIST 1.1."
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 4,
                    "description": "Adequate organ function as indicated by the following laboratory values up to first dose of study treatment: Hemoglobin\u2265 90 g/L, Absolute neutrophil count \u2265 1.5 x 109/L , Serum total bilirubin \u2264 1.5 x ULN (< 3 x ULN for participants with Gilbert syndrome ), AST and ALT\u2264 2.5 x ULN"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 5,
                    "description": "Active leptomeningeal disease or uncontrolled and untreated brain metastasis."
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 6,
                    "description": "Active autoimmune diseases or history of autoimmune diseases that may relapse"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 7,
                    "description": "Any active malignancy \u2264 2 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 8,
                    "description": "Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other immunosuppressive medication \u2264 14 days before the first dose of study treatment"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 9,
                    "description": "History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc."
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": null,
        "official_title": "A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors",
        "_phase_sort_order": 4,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Up to 3 years",
                "name": "Disease Control Rate (DCR) as assessed by the investigator",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Duration Of Response (DOR) as assessed by the investigator",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Accumulation Ratio for AUC of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Accumulation Ratio for Cmax of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Apparent clearance (CL/F) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Apparent volume of distribution (Vz/F) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Area under the concentration-time curve (AUC) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Half-life of (t1/2) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Metabolite to parent ratio for BGB-15025 and its metabolite",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Minimum observed plasma concentration (Cmin) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 4 Years",
                "name": "Phase 1a: Number of Participants Experiencing Adverse Events (AEs)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 4 years",
                "name": "Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 3 Years",
                "name": "Phase 1a: Number of participants with dose limiting toxicities (DLTs)",
                "description": "Participants will be considered evaluable for DLTs if they 1) received \u2265 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Phase 1a: Overall Response Rate (ORR) as assessed by the investigator",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1a: Time to maximum plasma concentration (Tmax) of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Phase 1b: Number of Participants Experiencing Adverse Events (AEs)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 1 year",
                "name": "Phase 1b: Number of participants with dose limiting toxicities (DLTs)",
                "description": "Participants will be considered evaluable for DLTs if they 1) received \u2265 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 2 years",
                "name": "Phase 1b: Overall Response Rate (ORR) as assessed by the investigator",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1b: Plasma Concentrations of BGB-15025",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Predose up to 8 hours postdose",
                "name": "Phase 1b: Plasma Concentrations of the metabolite",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "RDFE of BGB-15025 in combination with tislelizumab",
                "description": "The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 3 years",
                "name": "Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapy",
                "description": "The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Up to 3 Years",
                "name": "The maximum tolerated dose (MTD) of BGB-15025",
                "description": "The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%",
                "type_code": "PRIMARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT04649385",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2021-03-04",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Malignant Solid Neoplasm",
                    "Metastatic Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Solid Tumor",
                    "Advanced Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9270",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C148036",
                "name": "Unresectable Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C127156",
                    "C27359",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127156",
                "name": "Unresectable Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C27359",
                "name": "Unresectable Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "BGB-A317-15025-101",
        "active_sites_count": 2,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C141144",
                        "name": "Immune Checkpoint Modulator",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Enzyme Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C129825",
                        "name": "Antineoplastic Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129824",
                            "C471"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C2189",
                        "name": "Signal Transduction Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunotherapy Agent",
                            "Immune Mediators",
                            "Immunomodulating Agent",
                            "Immunomodulators",
                            "Immune Modulators",
                            "Immune Regulators",
                            "Immunotherapeutic Agent",
                            "Immunomodulatory Agent",
                            "BRM",
                            "Immunopotentiators",
                            "Biological Response Modifier",
                            "Biomodulators"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Protein Inhibitor",
                            "Antineoplastic Protein Antagonist"
                        ],
                        "nci_thesaurus_concept_id": "C129824",
                        "name": "Antineoplastic Protein Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C2189"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-tumor Targeted Therapy Agent",
                            "Molecularly Targeted Therapy Agent",
                            "Targeted Therapeutic Agent",
                            "Targeted Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunologic, Immunochemical",
                            "Biologics",
                            "Biologicals",
                            "Biological Products",
                            "Immunologics",
                            "Biopharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Antibody",
                            "Anticancer Antibody",
                            "Antineoplastic Ab"
                        ],
                        "nci_thesaurus_concept_id": "C129822",
                        "name": "Antineoplastic Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C129821"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Hematopoietic Progenitor Kinase 1 Inhibitor"
                        ],
                        "nci_thesaurus_concept_id": "C190784",
                        "name": "Hpk1 Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C129825"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Pharmaceuticals",
                            "Pharmacological Substance",
                            "Agent",
                            "Drug",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C143250",
                        "name": "Immune Checkpoint Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Drugs",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Cancer Agents",
                            "Antiproliferative Drugs",
                            "Anti-Tumor Agents",
                            "Antineoplastic Drugs",
                            "Tumor-Specific Treatment Agents",
                            "Antineoplastics",
                            "Antiproliferative Agents",
                            "Cancer Drug"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C121775",
                        "name": "Tislelizumab",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129822",
                            "C128037"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibody",
                            "Monoclonal Antibodies"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Drugs",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Cancer Agents",
                            "Antiproliferative Drugs",
                            "Anti-Tumor Agents",
                            "Antineoplastic Drugs",
                            "Tumor-Specific Treatment Agents",
                            "Antineoplastics",
                            "Antiproliferative Agents",
                            "Cancer Drug"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Biotherapeutic",
                            "Anticancer Biological",
                            "Anti-cancer Biological Agent",
                            "Antineoplastic Biological"
                        ],
                        "nci_thesaurus_concept_id": "C129821",
                        "name": "Antineoplastic Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C178833",
                        "name": "Hpk1 Inhibitor BGB-15025",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C190784"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "PD-1 Inhibitor",
                            "Protein PD-1 Inhibitor",
                            "Anti-PD-1 Agent",
                            "Programmed Cell Death Protein 1 Inhibitor",
                            "PD-1-targeting Agent"
                        ],
                        "nci_thesaurus_concept_id": "C124946",
                        "name": "PD1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C163758",
                            "C143250"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-PD-1 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128037",
                        "name": "Anti-PD1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C124946",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Enzyme Inhibitor Agent",
                            "Enzyme Inhibitor Drug",
                            "Enzyme Antagonist"
                        ],
                        "nci_thesaurus_concept_id": "C471",
                        "name": "Enzyme Inhibitor",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Pharmaceuticals",
                            "Pharmacological Substance",
                            "Agent",
                            "Drug",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Phase 1a: Dose Escalation",
                "description": "Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses\r\nPart B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy )",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Phase 1b: Dose Expansion",
                "description": "Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2021-03010",
        "why_study_stopped": null,
        "brief_summary": "The primary objective of this study is to assess the safety and tolerability of BGB-15025\r\n      alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD)\r\n      or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone\r\n      and in combination with tislelizumab in participants with advanced solid tumors.",
        "brief_title": "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors",
        "status_history": [
            {
                "status_date": "2021-03-04T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 330,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2021-03-04",
        "record_verification_date": "2023-02-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2024-08-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]